The Future of Treatment for Patients With Medullary Thyroid Cancer
August 15, 2017 – Katie Kosko
A Safety 'NET'
August 12, 2017 – Debu Tripathy, MD
Making Strides in Rare Cancers
August 13, 2017 – Mike Hennessy, Sr.
Comparing Male and Female Breast Cancer
August 14, 2017 – CHARLES L. SHAPIRO, M.D.
One Longtime NET Survivor's Quest to Educate Patients
August 10, 2017 – Arlene Weintraub
A Revolution in the Treatment of Neuroendocrine Tumors
August 09, 2017 – Arlene Weintraub
Angel in the Air for Patients With Cancer
August 09, 2017 – Katie Kosko
New Therapies Bring Hope to Rare Cancer Types
August 04, 2017 – Dara Chadwick
Immunotherapy Treatment Advances in Anal Cancer
August 03, 2017 – Meeri Kim
Hitting a Target in Gastrointestinal Stromal Tumors
August 02, 2017 – Erik Ness
Understanding Retroperitoneal Sarcoma
August 01, 2017 – WILLIAM TSENG, M.D.
Rare Cancer Reality
July 31, 2017 – Katie Kosko
On a Mission: Mesothelioma Survivor Fights for Awareness, Understanding and Hope
April 05, 2017 – Lauren M. Green
The Future of Treatment for Patients With Medullary Thyroid Cancer
August 15, 2017 – Katie Kosko
A Safety 'NET'
August 12, 2017 – Debu Tripathy, MD
Making Strides in Rare Cancers
August 13, 2017 – Mike Hennessy, Sr.
Comparing Male and Female Breast Cancer
August 14, 2017 – CHARLES L. SHAPIRO, M.D.
Currently Viewing
One Longtime NET Survivor's Quest to Educate Patients
August 10, 2017 – Arlene Weintraub
Angel in the Air for Patients With Cancer
August 09, 2017 – Katie Kosko
New Therapies Bring Hope to Rare Cancer Types
August 04, 2017 – Dara Chadwick
Immunotherapy Treatment Advances in Anal Cancer
August 03, 2017 – Meeri Kim
Hitting a Target in Gastrointestinal Stromal Tumors
August 02, 2017 – Erik Ness
Understanding Retroperitoneal Sarcoma
August 01, 2017 – WILLIAM TSENG, M.D.
Rare Cancer Reality
July 31, 2017 – Katie Kosko
On a Mission: Mesothelioma Survivor Fights for Awareness, Understanding and Hope
April 05, 2017 – Lauren M. Green

One Longtime NET Survivor's Quest to Educate Patients

Zuniga enjoys mentoring other patients as part of her volunteer work with the Arizona Carcinoid and Neuroendocrine Cancer Foundation. In February, she helped organize a panel discussion with physicians from Banner MD Anderson Cancer Center in Gilbert, Arizona, which was simulcast online so patients anywhere could learn about new treatment options and therapies that are in development. 
BY Arlene Weintraub
PUBLISHED August 10, 2017
JENNIFER ZUNIGA,
a NET and carcinoid
syndrome patient,
works at the University
of Arizona to help
educate patients to be
their own best advocate. - PHOTO BY MELISSA HOLLAND
JENNIFER ZUNIGA, a NET and carcinoid syndrome patient, works at the University of Arizona to help educate patients to be their own best advocate. - PHOTO BY MELISSA HOLLAND
JENNIFER ZUNIGA WAS STUNNED when she saw images of her neuroendocrine tumors (NETs) produced by a gallium 68 scan in 2015. She had been living with NETs since she was first diagnosed in 2001, but she hadn’t seen them so clearly until she was accepted into a clinical trial of gallium 68 CT/PET scans sponsored by the National Institutes of Health, during which she had three years’ worth of scans. “When you look at the gallium 68 scan it’s like high definition TV,” says Zuniga, who works as a health education administrator at the University of Arizona in Tucson. “It helps determine where the tumors are and informs your decisions of where you want to go with therapy.” 

Zuniga, a board member for the Arizona Carcinoid and Neuroendocrine Cancer Foundation, recounts her experiences in that trial — and her many other treatments — when she talks to patients and others at events sponsored by the organization. Zuniga has undergone eight surgeries since her first NET was discovered in a lymph node under her right arm. NETs were later found in her gastrointestinal tract and ovaries. 

During her 15 years as a patient with cancer, Zuniga has benefited from advancements in the diagnosis and treatment of NETs. She started taking somatostatin analogs soon after her diagnosis, and she underwent bowel surgery in 2002 — the combination of which, she says, “has been a lifesaver for me.” 

More recently, Zuniga has benefitted from the FDA approval of Xermelo to treat diarrhea caused by NETs in February 2017. Zuniga started suffering from diarrhea long before her NETs were diagnosed and had adjusted her diet to help calm her intestinal system. The drug works so well now, she says, “I’ve branched out in what I eat in public.” 

Zuniga enjoys mentoring other patients as part of her volunteer work with the Arizona Carcinoid and Neuroendocrine Cancer Foundation. In February, she helped organize a panel discussion with physicians from Banner MD Anderson Cancer Center in Gilbert, Arizona, which was simulcast online so patients anywhere could learn about new treatment options and therapies that are in development. 

Zuniga is now helping plan a session for the summer aimed at educating all patients with rare tumors, as well as an event to commemorate Neuroendocrine Awareness Day in November. The goal of these and other events sponsored by the foundation is to provide advice to patients on how best to describe their symptoms to their physicians so they can ensure they’re being offered the best treatments for them. “People are sometimes afraid to offend their doctors,” Zuniga says. “We want to educate patients with rare cancers to be their own best advocate.” 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In